181.33 0.00 (0.00%)
After hours: 5:47PM EST
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||179.12 - 181.97|
|52 Week Range||160.07 - 256.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.80 (1.58%)|
|1y Target Est||N/A|
A new wrinkle to an old treatment helped an East Bay company nearly double its stock price as it moves toward a regulatory decision on its drug for removing "frown lines" between the eyebrows. While the long-term prospects of Revance Therapeutics Inc. (RVNC) may rest more with the billion-dollar potential of its drug as a longer-lasting alternative to Botox for erasing facial wrinkles, the company is lining up clinical trials testing its drug as a therapeutic against neck spasms, a common foot ailment and other non-aesthetic conditions. "We've got no shortage of indications," said Revance President and CEO Dan Browne.
As we saw in Part 1 of this series, Johnson & Johnson (JNJ) is expected to report a 10.9% growth in revenue to $20.1 billion in 4Q17 compared to 4Q16. The above chart compares the actual revenues for Johnson & Johnson since 1Q16 and estimates for 4Q17. In 4Q17, the segment is expected to report growth in operating revenues, with a favorable impact from foreign exchange.
RBC Capital analysts argue Allergan could raise around $1 billion and send a "strong signal" on profitability with the sale of its anti-infectives business.
Bill Ackman’s $290 million settlement agreement with shareholders of drug developer Allergan plc has the support of a California federal judge. This is good news for the New York-based activist investor and Valeant Pharmaceuticals, as the two parties are being sued for insider trading. “The Court has vacated the trial date and indicated its preliminary approval of the settlement subject to submission of final papers and associated hearings,” Valeant said in a statement.
A federal judge signaled he would approve a $290 million settlement reached by Pershing Square, Valeant and the shareholders of Allergan who had alleged the two firms improperly profited from their failed ...
The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval. The Dec. 21 letter to San Diego-based Imprimis was posted on the FDA's website on Tuesday. Imprimis is contesting a lawsuit by rival Allergan Plc over allegations it is illegally selling and advertising unapproved drugs.
Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.
OKLAHOMA CITY (AP) — The first trial date has been set for a lawsuit by a state against pharmaceutical companies over the opioid epidemic, according to Oklahoma's attorney general.
Healthcare executives meeting at JP Morgan Conference agree that new tax reform is good, but how it will impact the sector is not yet entirely clear.
Pershing Square Holdings, the hedge fund operated by noted activist investor Bill Ackman, on Wednesday announced it was slashing its management fees, a move related to the settlement of two class-action ...
Also weighing was news overnight that the Bank of Japan had decide to taper its bond purchase program — a major sea change for a central bank that has really typified the extreme post-crisis money printing mentality. In the end, the Dow Jones Industrial Average gained 0.4%, the Nasdaq Composite gained 0.1%, the S&P 500 gained 0.1%, and the Russell 2000 broke the trend to fall 0.1%. Treasury bonds were hit hard, gold declined, and crude oil gained $1.64 to close at nearly $63-a-barrel.
Also weighing was news overnight that the Bank of Japan had decide to taper its bond purchase program — a major sea change for a central bank that has really typified the extreme post-crisis money printing mentality. At the industry level, auto and energy stocks led the way higher with gains of 1.8% and 1.5%, respectively.
COLUMBUS, Ohio (AP) — A federal judge on Tuesday set a goal of doing something about the nation's opioid epidemic this year, while noting the drug crisis is "100 percent man-made."
The Trump administration's tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017, according to senior executives from some of the largest pharmaceutical manufacturers. The $1.5-trillion bill, which U.S. President Donald Trump signed into law in December, lowers the income tax rate for U.S. companies to 21 percent from 35 percent, encourages them to repatriate cash, and modifies numerous deductions. Brent Saunders, chief executive officer of Allergan Inc (AGN.N), expects tax reform to finally clear the decks for big industry consolidation.
Allergan plc’s (NYSE:AGN) released its most recent earnings update in September 2017, which showed company earnings became less negative compared to the previous year’s level – great news for investorsRead More...
Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.